Last reviewed · How we verify
NCT04833439: FIND
The Effect of a Fasting MimickINg Diet on the Immune System
NA trial testing Fasting Mimicking Diet in Healthy Subjects in 16 participants. Completed in 28 April 2022.
1 April 2022
Quick facts
| Lead sponsor | Leiden University Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 16 |
| Start date | 1 November 2021 |
| Primary completion | 1 April 2022 |
| Estimated completion | 28 April 2022 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Fasting Mimicking Diet
Conditions studied
- Healthy Subjects — all drugs for Healthy Subjects →
- Cancer — all drugs for Cancer →
- Neoplasms — all drugs for Neoplasms →
Sponsor
Leiden University Medical Center
Who can join
18 and older, any sex, with Healthy Subjects or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Fasting or a Fasting Mimicking diet (FMD) can lower blood concentration of glucose and IGF1. Since cancer cells rely mostly on a glucose-based metabolism, FMD renders cancer cells more vulnerable to chemotherapy, thereby enhancing therapeutic efficacy. This process is known as differential stress sensitization (DSS). Another response to nutritional stress by fasting is known as differential stress resistance (DSR). DSR is a state in which healthy cells rather focus resources on protection and internal repair, which can result in reduced chemotherapeutic toxicity. Recent preclinical studies found that fasting or FMD not only aids healthy cell protection, but also has the potential to benefit effector T-cells and could thereby improve antitumor immunity. However in most oncotherapeutic clinical trials investigating the addition of a fasting regimen, other factors such as chemotherapy, surgery and additional medication affect the immune system as well. That is why this explorative study, conducted in healthy subjects, might be more suitable to investigate the immunological alterations upon FMD more specifically. This exploratory study aims to identify immunological alterations by using extensive immunoprofiling before and after three days of FMD in healthy subjects, as well as investigate possible side effects of FMD.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity.
de Gruil N, Pijl H, van der Burg SH, Kroep JR. · · 2022 · cited 24× · PMID 35326541 · DOI 10.3390/cancers14061390
Verify or expand the search:
- PubMed search for NCT04833439
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fasting Mimicking Diet
Trials testing the same drug.
- NCT06518798 — Feasibility and Preliminary Effects of Fasting-Mimicking Diet in Asian Americans With Prediabetes · NA · completed
- NCT06115551 — Fasting Mimicking Diet and Autophagy · NA · active not recruiting
- NCT06376604 — Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies · NA · recruiting
- NCT04908774 — Effects of a Fasting Mimicking Diet on Sperm Quality · NA · completed
- NCT04050475 — The Evaluation of the Efficacy of a Fasting Mimicking Diet Added to Functional Therapy for Depression · NA · completed
Other recruiting trials for Healthy Subjects
Currently open trials in the same condition.
- NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
- NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
- NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
- NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
- NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting
Other Leiden University Medical Center trials
Trials by the same sponsor.
- NCT07312565 — Occurrence of Abdominal Aortic Aneurysms in Patients With Aneurysmal Subarachnoid Hemorrhage · not yet recruiting
- NCT07090343 — Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement · Phase 3 · not yet recruiting
- NCT07498738 — Making Diabetes Care Fit for Young Adults Living With Type 1 Diabetes: Observations, Reflections and Expert Opinions · NA · not yet recruiting
- NCT06545292 — Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients · NA · recruiting
- NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04833439 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Leiden University Medical Center
- Last refreshed: 27 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04833439.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing